Senti Biosciences Inc
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(14,112) | $(12,111) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 1,204 | 1,258 |
| Depreciation | 926 | 984 |
| Change in fair value of GeneFab Note Receivable - related party | — | (29) |
| Change in fair value of GeneFab Economic Share - related party | — | (55) |
| Change in fair value of GeneFab Option - related party | — | (2,314) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 32 | 38 |
| GeneFab receivable - related party | (445) | 21 |
| GeneFab prepaid expenses - related party | 70 | 3,487 |
| Prepaid expenses and other assets | (265) | 192 |
| Operating lease right-of-use assets | 542 | 477 |
| Accounts payable | 357 | 389 |
| Accrued expenses and other current liabilities | (1,119) | (2,946) |
| Operating lease liabilities | (1,093) | (946) |
| GeneFab sublease deferred income - related party | (147) | (127) |
| Net cash used in operating activities | (14,050) | (11,682) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Purchases of property and equipment | — | (15) |
| Net cash used in investing activities | — | (15) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from CIRM Grant | 1,510 | — |
| Payment of issuance costs | (1,924) | — |
| Net cash used in financing activities | (414) | — |
| NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | (14,464) | (11,697) |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period | 51,815 | 39,448 |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period | $37,351 | $27,751 |
| SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION: | ||
| Purchases of property and equipment in accounts payable and accrued expenses | $170 | $— |
| Unpaid issuance costs | $605 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.